Ganitumab failure in pancreatic cancer another setback for Amgen/Takeda alliance
This article was originally published in Scrip
Executive Summary
Amgen and its Japanese development partner Takeda have halted the GAMMA Phase III multinational trial with ganitumab (AMG 479), after an interim analysis showed that the monoclonal antibody was likely to miss its overall survival primary endpoint in the pancreatic cancer study.
You may also be interested in...
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Asahi Paying $1.3bn For One-Product Veloxis
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
Ebb TIDES As Takeda’s Dengue Contender Weaker At 18 Months
Takeda's TAK-003 generally positive in new 18-month analysis, but efficacy falls versus 12 months and lowest effectiveness again seen against serotype 3.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports